Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

NCT02165826 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1323

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Roflumilast
DRUG: Roflumilast Placebo
DRUG: Standard of Care COPD Treatment

Sponsor

AstraZeneca